play_arrow

keyboard_arrow_right

replay_10 skip_previous play_arrow skip_next forward_10
00:00 00:00
playlist_play chevron_left
volume_up
play_arrow

Diabetes Drugs: Bittersweet Truth of Patent Expiries

Kiran Somvanshi July 26, 2022


Background
share close

With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with Nithya Balasubramanian, Director at AB Bernstein, Sheetal Sapale, Marketing President – AWACS, and Vikas Dandekar, Editor – Pharma at ET Prime.
Credits: CNBC-TV18

Credits : Producers: Vinay Joshi from The Economic Times and Soundarya Jayachandran from Aawaz. Sound editors: Indranil Bhattacharjee from the Economic Times and Swati Joshi from Aawaz Executive Producers : Arijit Barman and Anupria Bahadur from The Economic Times.